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Background: Sickle cell disease (SCD) is common in many parts of sub-Saharan Africa (SSA), where it is associated
with high early mortality. In the absence of newborn screening, most deaths among children with SCD go
unrecognized and unrecorded. As a result, SCD does not receive the attention it deserves as a leading cause of
death among children in SSA. In the current study, we explored the potential utility of verbal autopsy (VA) as a tool
for attributing underlying cause of death (COD) in children to SCD.
Methods: We used the 2007 WHO Sample Vital Registration with Verbal Autopsy (SAVVY) VA tool to determine
COD among child residents of the Kilifi Health and Demographic Surveillance System (KHDSS), Kenya, who died
between January 2008 and April 2011. VAs were coded both by physician review (physician coded verbal autopsy,
PCVA) using COD categories based on the WHO International Classification of Diseases 10th Edition (ICD-10) and by
using the InterVA-4 probabilistic model after extracting data according to the 2012 WHO VA standard. Both of these
methods were validated against one of two gold standards: hospital ICD-10 physician-assigned COD for children
who died in Kilifi District Hospital (KDH) and, where available, laboratory confirmed SCD status for those who died
in the community.
Results: Overall, 6% and 5% of deaths were attributed to SCD on the basis of PCVA and the InterVA-4 model,
respectively. Of the total deaths, 22% occurred in hospital, where the agreement coefficient (AC1) for SCD between
PCVA and hospital physician diagnosis was 95.5%, and agreement between InterVA-4 and hospital physician diagnosis
was 96.9%. Confirmatory laboratory evidence of SCD status was available for 15% of deaths, in which the AC1 against
PCVA was 87.5%.
Conclusions: Other recent studies and provisional data from this study, outlining the importance of SCD as a cause of
death in children in many parts of the developing world, contributed to the inclusion of specific SCD questions in
the 2012 version of the WHO VA instruments, and a specific code for SCD has now been included in the WHO and
InterVA-4 COD listings. With these modifications, VA may provide a useful approach to quantifying the contribution
of SCD to childhood mortality in rural African communities. Further studies will be needed to evaluate the
generalizability of our findings beyond our local context.
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Sickle cell disease (SCD) [1,2] represents a growing health
problem both in Africa and in populations of African ori-
gin [3]. In a recent study, we estimated that, currently,
more than 300,000 children are born with SCD worldwide
every year [3]. Approximately three-quarters of these
births occur in sub-Saharan Africa (SSA), where facilities
for the diagnosis and treatment of SCD are few. As a
result, between 50 and 90% of children born with SCD on
the continent die undiagnosed in the first 5 years of life
[4]. The combination of these high birth rate and mortal-
ity figures mean that SCD currently accounts for more
than 6% of all deaths among children younger than 5 years
in SSA [5].
Poor awareness of SCD among health leaders, com-
bined with a lack of facilities for proper diagnosis and
care, means that few data are available regarding such
basic questions as the modes and age profile of deaths
among children with SCD throughout much of SSA.
Recognizing this knowledge gap, we investigated whether
verbal autopsy (VA), in which a structured questionnaire
is administered to the relatives of deceased people, with a
view to ascertaining the probable causes of death, might
be one potential approach to investigating the contribu-
tion of SCD to childhood deaths in areas where facilities
for diagnosis are suboptimal. Here we present data from a
study in which we investigated the utility of VA as a tool
for diagnosing SCD among children dying in Kilifi County
on the coast of Kenya.
Methods
Ethics approval
Ethics permission was granted by the KEMRI/National
Ethics Review Committee (ERC) in Nairobi and VAs were
only administered after obtaining written informed consent
from potential respondents.
Study area
The study was conducted within the area served by
the Kilifi Health and Demographic Surveillance System
(KHDSS) on the coast of Kenya [6]. Established in October
2000, the KHDSS serves as a framework for population-
based epidemiological studies of diseases of local import-
ance, monitors mortality trends, and is used to test and
evaluate the impact of public health interventions. The
KHDSS covers an area of 891 km2 and includes a resident
population that currently numbers approximately 260,000.
Between 1,200 and 1,500 deaths are recorded each year, of
which 240 to 300 are among children older than 28 days
and younger than 14 years of age. More than 60% of these
deaths occur outside hospital, and their causes are rarely
recorded.
Kilifi District Hospital (KDH) provides primary care
for the residents of the KHDSS, serving a population ofapproximately 125,000 children younger than 14 years, and
acting as a first-referral hospital for healthcare facilities
throughout Kilifi District [7]. The KHDSS forms one com-
ponent of an integrated health surveillance system: resi-
dents of the area are identified at the point of admission
to KDH, where their clinical data are immediately entered
onto a computerized database, along with the results of a
range of routine laboratory investigations [6]. KDH is the
only health facility in Kilifi District that provides specialist
care to children with SCD.
Study population and cause of death assignment using
verbal autopsy
In collaboration with the Kenyan Ministry of Health
(MOH), the KHDSS began collecting VA data in 2008
with the aim of documenting the pattern of underlying
cause of death (COD) in the community [8]. The current
analysis focuses on residents of the KHDSS area aged
28 days to 14 years who died between January 2008 and
April 2011. VAs were administered for these children
using the standard 2007 WHO Sample Vital Registration
with Verbal Autopsy instrument [8]. VAs were reviewed
and coded to provide a maximum of two underlying
CODs by two separate methods. First, we used conven-
tional physician coded verbal autopsy (PCVA) in which
two independent clinicians reviewed each questionnaire
and indicated the underlying COD. As described previously
[8], to facilitate comparisons between COD assignment by
PCVA and COD assignment by physicians on the hospital
wards, the PCVA coding in the current study followed
the longer COD list described in the WHO Inter-
national Classification of Diseases and Related Health
Problems 10th revision (ICD-10) [9] rather than the
more restricted list that is normally used with the
WHO 2007 instruments. Importantly, for the purposes
of the current study, unlike the restricted WHO 2007
COD list, the ICD-10 list included a code for SCD.
Where the two clinicians disagreed or where one could
not make a diagnosis, a third clinician was consulted. A
COD was assigned when two clinicians agreed on the
COD. In instances where there was no agreement
between the three clinicians, a consensus COD was
reached through arbitration. None of the clinicians had
access to data regarding the name or SCD status
(affected or unaffected) of deceased and no predeter-
mined diagnostic algorithms were used to attribute
CODs to SCD. For the purpose of this analysis, assess-
ments were specifically categorized according to
whether or not SCD was mentioned among the under-
lying CODs. Second, we also used the freely available
InterVA-4 computer-based probabilistic model [10] to
assign CODs. The 2012 WHO SCD indicator did not
map directly to any specific question contained in
our questionnaires, which were based on the 2007
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captured in the free-text sections of the VA forms, for
which we developed an automated search for 'sickle OR
scd' and mapped it onto the SCD indicator.
COD assignment in the pediatric ward at KDH
High-quality clinical and laboratory data were available
for a subset of children who died in KDH [8]. In order
to facilitate comparisons between these different methods
of COD assignment, we mapped the ICD-10 COD codes
generated by both PCVA and by the hospital physicians
to conform to the 2012 WHO VA COD categories that
are used by the InterVA-4 software [11] (see Additional
file 1).
Confirmatory laboratory evidence for SCD
Worldwide, a number of genotypes manifest phenotypically
as SCD. The principal genotypes include homozygosity
for the βs mutation of the HBB gene (HbSS), sickle cell-
hemoglobin C disease (HbSC) and sickle cell-β-thalassemia.
HbSS is the only significant cause of SCD in Kenya [12].
Results of blood tests for HbS typing, conducted by ei-
ther cellulose acetate hemoglobin electrophoresis (Helena
Laboratories, Beaumont, TX, USA) or by high perform-
ance liquid chromatography (Variant Analyzer, BioRad,
Hercules, CA, USA), were available for a subset of chil-
dren who were either tested during the course of their ad-
mission to KDH or who were members of two prospective
cohort studies: (i) the Kilifi Sickle Cell Disease (KSCD)
study [13] or the Kilifi Genetic Birth Cohort (KGBC)
study [14]. We quantified the contribution of SCD to
childhood mortality according to VA, and validated the
results in the subset of deaths in children who had been
involved in any of these studies, and for whom there
was therefore laboratory data that confirmed or refuted
a diagnosis of SCD HbSS.
Data handling
First, we compared data on the underlying CODs recorded
by the two VA clinicians to determine inter-reviewer agree-
ment. Second, we compared the underlying CODs reached
by PCVA consensus against the InterVA-4 model. Third,
for those who had died in KDH, we validated the CODs
assigned by PCVA and the InterVA-4.02 model against
the COD recorded through the KDH pediatric ward
surveillance system. Where more than one COD was
given, we selected the underlying COD as our unit of
comparison between the VA and pediatric ward COD.
Finally, we validated the VA CODs in the subset of deaths
with available laboratory data.
Statistical analysis
We used the agreement coefficient of Gwet (AC1) [15,16]
to measure levels of agreement (see Additional file 2).Sensitivity and specificity were also calculated to measure
diagnostic validity of the VA tool and InterVA-4 model in
identifying deaths due to SCD.
Data were transformed using SAS® v.9.2 (SAS Institute
Inc., Cary, NC, USA) software and all analyses carried
out using R v3.0.0 [17].Results
Total deaths recorded and VAs administered
During the period of the study, a total of 750 deaths
among children aged between 28 days and 14 years were
recorded through the KHDSS. VAs were administered
and PCVA and InterVA-4.02 applied to 610 (81.3%) of
these deaths. VAs were omitted for the following rea-
sons: movement of the family from the study area (86;
11.5%), no appropriate respondent identified (30; 4.0%)
and refusal of relatives to be interviewed (8; 1.1%). No
reason was given for 16 (2.1%). Of those with com-
pleted VAs, the median age at death was 2.0 years; 452
(74%) were children aged under 5 years, of whom 262
(58%) were infants. Of the 610 children, 334 (55%)
were male. Regarding place of death, 45% of children
died in their homes, 43% died in hospital and 12% died
elsewhere.Agreement between PCVA coders
The cause-specific mortality fractions (CSMFs) assigned
by the two primary PCVA coders are summarized in
Figure 1 and Additional file 3. The most common diagno-
ses assigned by both clinicians were malaria, malnutrition,
bacterial meningitis, pneumonia, congenital malformations,
and SCD. Agreement between the two PCVA coders varied
by diagnosis. For example, PCVA coder 1 attributed 84
(14%) and 33 (5%) of the total 610 deaths to malaria and
HIV respectively, whereas PCVA coder 2 attributed 96
(16%) deaths to malaria and 21 (3%) to HIV. In addition,
PCVA coder 1 attributed 65 (11%) deaths to malnutri-
tion, while PCVA coder 2 attributed only 34 (6%). The
overall inter-coder agreement (AC1) for all deaths was
54.6% (Table 1), corresponding only to a moderate to
high level of agreement [15]. Conversely, however, the
AC1 for deaths due to SCD was very high [15], at 97.3%
(Table 1). Coders did not include SCD in their list of
underlying causes of death on the basis of any fixed
algorithms, but treated each VA on a case-by-case basis.
In some cases, SCD was included under questions 511
and 512, which enquired about pre-existing conditions,
in others, the coders appeared to have formed their view
on the basis of the free-text elements at the end of the
form, which sometimes described characteristic features
of SCD, or on the basis of specific responses to ques-
tions within the form. Two such questions that ap-
peared to have particular influence were questions 869
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Figure 1 Cause-specific mortality fractions (CSMFs) for 610 child deaths interpreted by verbal autopsy (VA) coders. CSMFs for 610
deaths of children aged less than 14 years in the Kilifi Health and Demographic Surveillance System (KHDSS) study area, derived from verbal
autopsies interpreted by two independent physician coders.
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respectively.Agreement between PCVA consensus and the
InterVA-4 model
The CSMFs assigned by PCVA and by the InterVA-4
model are summarized in Figure 2 and Additional file 3.
The InterVA-4 model assigned more deaths (13%) to
HIV than did PCVA (5%), whereas PCVA attributed 8%
of deaths to malnutrition, while the InterVA-4 model
attributed only 3%. CSMFs obtained between the InterVA-
4 model and PCVA were within ±2% for the other diagno-
ses, as shown in Figure 2 and Additional file 3. The AC1
for all deaths was 50.6%, while the AC1 for deaths due to
SCD was very high, at 94.6% (Table 1). We noted that the
assignment of SCD as the underlying COD both by PCVA
and by the InterVA-4 model was strongly influenced byTable 1 Agreement between the four validation methods in d
Methods AC1 for all CO
PCVA coder 1 versus PCVA coder 2 (n = 610) 54.6 (2.0) (50.7
InterVA-4 model versus PCVA consensus (n = 610) 50.6 (5.0) (48.7
InterVA-4 model versus paediatric ward COD (n = 134) 42.5 (3.6) (35.4.
PCVA consensus versus pediatric ward COD (n = 134) 50.0 (5.1) (40.0
PCVA consensus versus laboratory evidence (n = 93) –
AC1, Agreement coefficient of Gwet; CI, confidence interval; COD, cause of death; SCinformation contained within the free-text section of the
questionnaires.Agreement between CODs determined by PCVA, the
InterVA-4 model, and by clinicians on the KDH
pediatric ward
COD was available from the pediatric ward for 134/610
(22%) of children with VA data, for whom we were able
to compare data regarding the underlying CODs assigned
by the attending clinicians with that assigned both
by PCVA and by the InterVA-4 model (Figure 3; see
Additional file 3). The CSMFs obtained between PCVA
and the InterVA-4 model against the KDH pediatric ward
COD were within ±2% for SCD, meningitis, congenital
malformation, and diarrheal diseases. PCVA and the
InterVA-4 model attributed 13% and 5% of deaths
to pneumonia respectively, while 19% of deaths wereetermining the causes of children’s deaths
Ds, % (SE) (95% CI) AC1 for COD due to SCD, % (SE) (95% CI)
to 58.5) 97.4 (0.6) (95.9 to 98.7)
to 57.2) 94.6 (0.9) (95.0 to 99.0)
0 to 49.6) 96.9 (1.5) (95.0 to 99.0)
to 60.0) 95.5 (1.8) (92.0 to 99.0)
87.5 (4.4) (78.9 to 96.1.)
D, sickle cell disease. SE, Standard error; VA, verbal autopsy.
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Figure 2 Cause-specific mortality fractions (CSMFs) for 610 child deaths interpreted by physician coded verbal autopsy (PCVA) and the
InterVA-4 model. CSMFs for 610 deaths of children aged less than 14 years in the Kilifi Health and Demographic Surveillance System (KHDSS)
study area, derived from verbal autopsies interpreted by PCVA and the InterVA-4 model.
Ndila et al. BMC Medicine 2014, 12:65 Page 5 of 9
http://www.biomedcentral.com/1741-7015/12/65attributed to pneumonia on the pediatric ward. Similarly,
PCVA and the InterVA-4 model assigned almost twice
as many deaths to malaria as did clinicians on the
pediatric ward. The InterVA-4 model attributed 12% of
deaths to HIV/AIDS, whereas the PCVA and the0%
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Figure 3 Cause-specific mortality fractions (CSMFs) for 134 child deaths
model and pediatric hospital cause of death (COD). The figure shows CSM
InterVA-4 model were compared against the COD given by physicians for thopediatric ward clinicians attributed 5% and 6% of deaths
respectively. By contrast, the InterVA-4 model attrib-
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Ndila et al. BMC Medicine 2014, 12:65 Page 6 of 9
http://www.biomedcentral.com/1741-7015/12/65clinicians attributed 5%, 6% and 5% of deaths, respect-
ively, to SCD.
Validation of VA against gold standards
Overall, the AC1 between CODs ascribed by PCVA con-
sensus and those assigned by physicians on the pediatric
ward was 50.0%, defined as only a moderate to high level
of agreement. Similarly, the AC1 between the CODs
assigned by the InterVA-4 model and those assigned on
the pediatric ward was only 42.5% (Table 1). However,
the AC1 with regard to the specific diagnosis of SCD
was 95.5% and 96.9%, respectively, for physician coded
VA and the InterVA-4 model (Table 1), consistent with a
very high level of agreement. Although physicians on the
pediatric ward did not include SCD as one of their
underlying CODs on the basis of any fixed diagnostic
algorithms, they had the considerable advantage over the
PCVA and InterVA-4 methods of being able to take a
detailed clinical history, perform a clinical examination,
and access specialist tests. In a number of cases, patients
were already known attenders at a SCD clinic, and were
taking regular prophylaxis for malaria and bacterial dis-
eases. In other cases, patients had a characteristic feature
of SCD within their previous medical history, such as a
previous admission to hospital in infancy with swollen
hands and feet, recurrent admission to hospital with pain
in the arms or legs, or frequent admission to hospital with
anemia requiring transfusion. In a further group of
children, the clinicians’ suspicions appear to have been
aroused by findings on clinical examination such as
jaundice or splenomegaly, or through observation of
the characteristic facial features of SCD. In addition,
clinicians had access to data on full blood counts and
the ability to confirm their clinical suspicion by blood
film examination and electrophoresis. Taking the pediatric
ward COD as the gold standard for these reasons, the ob-
served sensitivities and specificities for both the PCVA
and InterVA-4 methods across the top 10 major CODs
are presented in Table 2. The sensitivity with regard to the
diagnosis of SCD was 83% in the case of both PCVA and
of VAs interpreted using InterVA-4, while the specificity
was 98% and 99%, respectively.
Agreement between PCVA consensus and confirmatory
laboratory evidence
To further assess the validity of the VA tool with regard
to the identification of deaths attributable to SCD, we
also reviewed the COD data determined by VA in the
subset of 93 children (15% of 610) for whom laboratory
evidence regarding SCD status was available. Of these,
62 (67%) children were phenotype HbAA (normal), 11
(12%) were HbAS (heterozygous carriers) and 20 (21%)
were HbSS (that is, they had SCD). The SCD-specific AC1
between COD by PCVA and the laboratory phenotypewas 87.5% (Table 1). Taking the laboratory data as the gold
standard, the sensitivity and specificity of COD according
to PCVA for a diagnosis of SCD were 76.9% and 96.6%,
respectively.
Discussion
Although common, SCD remains neglected in many parts
of SSA [18]. Few countries have programs for the early
diagnosis or specialist treatment of SCD, and the majority
of those affected therefore continue to die undiagnosed
during early childhood [4]. Although infections, including
bacterial diseases [19] and malaria [7,20,21], are widely
regarded as probable causes of this early mortality, to a
large extent the natural history of SCD in African pop-
ulations remains poorly documented [18].
In this study, we investigated the question of whether
VA might prove a useful approach to the identification of
deaths due to SCD in populations for which more robust
data on COD are not available. If VA does prove reliable
then it could provide a useful tool for improving knowledge
on the epidemiology of SCD in resource-poor settings,
which could also be helpful both for advocacy and for
public health planning.
Consistent with previous studies [22-28], we found
that PCVA performed better for some diagnoses than
for others. A single previous study was conducted in the
same population, which aimed to validate VA against
COD data from the hospital wards [25]. In that study,
VA was associated with the following sensitivities, speci-
ficities and positive predictive values with regard to the
attribution of CODs in children older than 1 month,
which were broadly similar to those in the current study:
acute respiratory infection 28%, 91%, and 29%, respect-
ively; meningitis 38%, 94%, and 20%; and malnutrition
89%, 96%, and 87%. Conversely, the sensitivity of VA for
the attribution of malaria was somewhat higher in the
current (83%) than in the previous study (46%), although
specificity and positive predictive values were similar in
both (90% versus 89% and 50% versus 57%, respectively).
Measles, a common COD in the earlier study, did not
feature among the top 10 diagnoses in the current study,
whereas HIV did. Some of these differences might be ex-
plained by changes that have been made to the VA tools
since the earlier study was conducted, but there have
also been significant changes in the patterns of morbidity
and mortality in the community in the intervening period.
Malaria, previously the single most common cause of ad-
mission and death at KDH, has declined significantly in
recent years [29], universal childhood vaccination against
measles has been introduced, and the HIV epidemic has
become well established.
The main focus of the current manuscript, however,
is SCD. We found that COD attribution by VA for
this diagnosis was consistently good from a number of
Table 2 Validation results for the InterVA-4 model and PCVA consensus against the pediatric ward COD for the top ten
CODs among 134 child deaths
Cause of death Sensitivity, % Specificity, % PPV% NPV%
InterVA-4 PCVA consensus InterVA-4 PCVA consensus InterVA-4 PCVA consensus InterVA-4 PCVA consensus
1.05: Malaria 80 83 83 90 38 50 97 97
1.02: Pneumonia 14 28 94 91 14 41 81 85
3.02: Severe malnutrition 10 47 97 91 10 44 87 92
98: Other unspecified
non-communicable disease
9 18 100 92 100 17 92 93
10.06: Congenital malformation 55 73 98 98 67 73 96 98
1.07: Meningitis 12 44 91 94 15 33 93 96
1.03: HIV/AIDS 40 43 88 95 18 24 94 93
1.04: Diarrheal diseases 29 29 96 98 29 40 96 96
4.03: Sickle cell with crisis 83 83 99 98 83 63 99 99
NPV, negative predicted value; PCVA, physician coded verbal autopsy; PPV, positive predictive value.
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erably higher for SCD (97.3%) than for all other diagnoses
combined (54.6%) (Table 1). Second, agreement between
the InterVA-4 model and hospital COD was considerably
higher for SCD (96.9%) than for other diagnoses com-
bined (42.5%) (Table 1). Third, agreement between
PCVA data and hospital COD was considerably higher
for SCD (95.5%) than for other diagnoses combined
(50%) (Table 1). Finally, agreement between VA coded
data and laboratory-proven SCD was also high at 87.5%
(Table 1). Moreover, the proportion of all deaths that were
attributed to SCD by VA (6%) was in broad agreement
with that predicted from other studies in Africa [5], and is
also consistent with that we would predict within the Kilifi
population. During the period covered by this study, over-
all mortality among children aged 1 month to 15 years
was in the region of 40/1000, while around 0.8% of all
births are affected by SCD [19]. Assuming that 50% of
these children die during the first 5 years of life, and that
most of these deaths occur after the first month of life [4],
SCD should account for around 10% of all deaths among
children of this age. Taken together, therefore, these data
suggest that the VA method can deliver a plausible esti-
mate of the burden of SCD in our study population.
It is noteworthy that SCD did not feature as a diagno-
sis either in the previous validation study conducted in
Kilifi [25] or in other similar studies [24,27]. The most
likely explanation is that no specific code for SCD was
included in the shortlist of codes used in these previous
VA studies. This is certainly true for the Kilifi study,
where deaths from SCD will most likely have been dis-
tributed between the classifications 'anemia' and 'others'.
Similarly, no specific code for SCD was included even in
much larger validation studies such as those published
by Setel and colleagues [30] or by Murray and colleagues
[31]. Of note, in the latter study, the authors stated thattheir cause list was constructed based on the WHO Global
Burden of Disease estimates of the leading causes of death,
potential to identify unique signs and symptoms, and the
likely existence of sufficient medical technology to ascertain
gold standard cases. This is of particular concern be-
cause it reflects the low visibility that SCD currently
holds in the eyes of the international health community,
despite accounting for rising proportion of declining
deaths in children under 5 years of age. In the current
study, we used the longer ICD-10 category list for our
COD assignment by both PCVA and by hospital physi-
cians, and the WHO 2012 cause list for our COD as-
signment by InterVA-4. While it is obvious that the
absence of a code for SCD in previous code lists will
have led to a systematic underestimation of SCD as a
COD (to the point of absence) in previous studies, we
cannot exclude the possibility that the use of these lon-
ger cause lists might have led to an overestimation of
SCD as a COD in the current study; further work will
be required to investigate this possibility in the future.
During the current study we noted that no specific
questions relating to SCD were included in the 2007
WHO VA forms, and that the attribution of SCD as the
underlying COD both by PCVA and by the InterVA-4
model therefore leant heavily on the free-text element of
the questionnaires. Increasing awareness of the import-
ance of SCD as a major COD in the African context from
a number of recent studies [4,5,19,32], and provisional
data from this study has now led to the inclusion within
the 2012 version of the WHO Verbal Autopsy Instrument
of a specific question regarding SCD [11]. Similarly, a
specific code for SCD has also now been included in
the list of CODs formulated by WHO for VA use, and
can also be assigned by the InterVA-4 model. The full
process by which this decision, and the decision to
introduce or to drop other specific CODs from the
Ndila et al. BMC Medicine 2014, 12:65 Page 8 of 9
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Leitao and colleagues [33].
Although our study provides new evidence that VA
has potential as a tool for identifying deaths due to SCD,
it is open to a number of criticisms. Perhaps most im-
portantly, SCD constitutes a major research interest at
our program [7,13,19,20] and, as a result, it is possible
that our coding clinicians are unusually well versed in
the signs and symptoms of SCD. We aimed to mitigate
against this bias by applying the InterVA-4 model, which
at least guarantees consistency and comparability with
possible future studies elsewhere. Similarly, in order to
validate our COD assignment by VA, we used as our
gold standard COD assignment by a clinician for the
subset of deaths that occurred in hospital. We cannot
be sure that the distribution of CODs among deaths that
occur in hospital is fully representative of CODs overall,
and this could potentially lead to an unrecognized and
unmeasurable bias. Nevertheless, we suggest that our
study would benefit from replication and validation at
other sites.
We have previously estimated that approximately 240,000
children are born with SCD annually in Africa alone [3]
and that 50-90% of these children die undiagnosed in their
first few years of life [4]. Others have estimated that this
means that SCD accounts for around 6% of all child
deaths in SSA [5], placing SCD firmly on the list of leading
causes of death, at least in countries where the gene
frequency is high. This is recognized by the welcome
inclusion of the hemoglobinopathies in the latest round of
the Global Burden of Disease Study [34]. Nevertheless,
much more remains to be done to raise the profile of SCD
on the global health agenda.
Conclusion
In summary, we have presented data suggesting that VA
might provide a useful approach to investigating the
contribution of SCD to childhood deaths in one part of
SSA. We hope that our study will prompt similar work
in other parts of Africa, including the further exploration
of automated approaches to VA coding that might be
generalized to other settings.Additional files
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